Akebia Therapeutics, Inc. granted five newly-hired employees options to purchase an aggregate of 10,450 shares of Akebia’s common stock on April 30, 2018.
The options have an exercise price of $9.21 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of the company’s Inducement Award Program and a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180502005292/en/
Contacts
Akebia Therapeutics
John Garabo, 617-844-6130
Director, Corporate Communications
jgarabo@akebia.com
Source: Akebia Therapeutics, Inc.
